Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 3
1999 3
2000 1
2001 3
2002 1
2003 2
2004 5
2005 1
2008 2
2009 1
2012 1
2013 4
2014 2
2015 1
2016 1
2017 1
2018 5
2019 3
2020 8
2021 6
2022 3
2023 5
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Saad F, et al. J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798. Online ahead of print. J Clin Oncol. 2024. PMID: 39279580
Update on the treatment of metastatic renal cell carcinoma.
Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Medina López RA, et al. World J Clin Oncol. 2022 Jan 24;13(1):1-8. doi: 10.5306/wjco.v13.i1.1. World J Clin Oncol. 2022. PMID: 35116228 Free PMC article.
Role of the urologist in the treatment of renal cancer.
Juárez-Soto A, Chantada-Abad V, Alvarez Ossorio-Fernández JL, Carballido-Rodriguez J, Llarena-Ibarguren R, Medina-López RA, Moreno-Jiménez J, Cózar Olmo JM. Juárez-Soto A, et al. Among authors: medina lopez ra. Actas Urol Esp (Engl Ed). 2018 Oct;42(8):483-484. doi: 10.1016/j.acuro.2018.03.005. Actas Urol Esp (Engl Ed). 2018. PMID: 29773454 English, Spanish. No abstract available.
[Recurrence and progression after BCG.].
Lendínez-Cano G, Rivero-Belenchón I, Medina-López RA. Lendínez-Cano G, et al. Among authors: medina lopez ra. Arch Esp Urol. 2020 Dec;73(10):929-933. Arch Esp Urol. 2020. PMID: 33269711 Free article. Spanish.
[Retroperitoneal neurilemmona].
Argüelles Salido E, Congregado Ruiz CB, Medina López RA, Pascual del Pobil Moreno JL. Argüelles Salido E, et al. Among authors: medina lopez ra. Actas Urol Esp. 2004 Sep;28(8):628-30. doi: 10.1016/s0210-4806(04)73148-4. Actas Urol Esp. 2004. PMID: 15529934 Review. Spanish.
[Renal transplant recipient evaluation.].
Parra López ML, Lozano-Blasco JM, Martínez-Rodríguez J, León-Dueñas E, Medina-López RA. Parra López ML, et al. Among authors: medina lopez ra. Arch Esp Urol. 2021 Dec;74(10):941-952. Arch Esp Urol. 2021. PMID: 34851309 Free article. Spanish.
65 results